Kisspeptin

Also known as: Kisspeptin-10, Kp-10, Kisspeptin-54, Kp-54

Evidence Tier Bmedium riskadvancednot approved

Upstream regulator of reproductive axis (GnRH/LH/FSH). FDA-flagged for compounding concerns.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Overview

Kisspeptin is an upstream regulator of the reproductive axis, stimulating GnRH neurons to drive LH/FSH release. Human volunteer studies include IV bolus dosing with kisspeptin-10 showing LH peak within ~45 minutes, maximal stimulation at ~1 Âµg/kg. FDA flagged kisspeptin-10 for compounding safety with limited safety data and immunogenicity concerns. WADA lists it as a peptide hormone.

Research Details

Mechanism of Action

Upstream regulator of reproductive axis via stimulation of GnRH neurons, driving LH/FSH release.

Study Dose Range

Human: IV bolus with maximal LH stimulation at ~1 Âµg/kg (Kp-10).

Administration Routes

intravenous, subcutaneous

Onset / Timeline

Acute LH response within ~45 minutes; fertility endpoints context-specific.

Expected Effects

LH/FSH axis stimulation; fertility research applications.

Adverse Effects

FDA: limited safety data, immunogenicity concerns for compounding.

Contraindications

No formal label; high endocrine interaction potential.

Interaction Notes

High endocrine interaction potential with GnRH analogues and gonadotropins. Do not provide stacking guidance.

Related Goals

Sexual Health & Libido

Known Interactions

caution with Oxytocin

HPG-axis signaling overlap; FDA flags kisspeptin-10 compounding uncertainty.

Available From

No vendors currently listed for this peptide.

Frequently Compared

Melanotan II

Unlicensed broad melanocortin agonist with pigmentation and sexual side-effect profiles. Highest compliance risk.

Tier C

PT-141

FDA-approved melanocortin agonist (Vyleesi) for HSDD in premenopausal women. Prescription only.

Tier A

Oxytocin

Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.

Tier A

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.